Zheng Chunlan, Hu Minhui, Gao Feng
a Department of Internal Medicine - Section 5 , Wuhan Pulmonary Hospital (Wuhan Tuberculosis Control Institute) , Wuhan , P.R. China.
b Department of Endocrinology, Union Hospital, Tongji Medical College , Huazhong University of Science and Technology , Wuhan , P.R. China.
Glob Health Action. 2017;10(1):1-11. doi: 10.1080/16549716.2016.1264702.
The double burden of tuberculosis (TB) and diabetes mellitus (DM) is hitting certain Asian countries harder than other areas. In a global estimate, 15% of all TB cases could be attributable to DM, with 40% of those cases coming from India and China. Many other countries of South, East, and South-East Asia are of particular concern given their TB burdens, large projected increases in DM prevalence, and population size.
In this narrative review, we aimed to: (i) give an overall insight into the evidence on TB-DM epidemiology from high double burden Asian countries, (ii) present the evidence on bi-directional screening implementation in this region, (iii) discuss possible factors related to higher TB susceptibility of Asian diabetic patients, and (iv) identify TB-DM comorbidity treatment challenges.
The PubMed and Google Scholar databases were searched for all studies addressing DM/TB epidemiology, bi-directional screening and management in South, East and South-East Asia.
We identified the DM prevalences among TB patients as ranging from approximately 5% to more than 50%, whereas TB prevalences among diabetic patients were 1.8-9.5 times higher than in the general population in developing Asian countries. Evidence from studies designed to address diagnosis and treatment of the dual disease in these critical regions is scarce as well as the evidence related to possible DM patients' genetic and acquired predisposition for TB.
More prospective studies specifically designed to address adequate screening techniques, identify patients at risk, and define an adequate treatment of dual disease in this region are needed without delay.
结核病(TB)和糖尿病(DM)的双重负担对某些亚洲国家的影响比对其他地区更为严重。据全球估计,所有结核病病例中有15%可归因于糖尿病,其中40%的病例来自印度和中国。鉴于南亚、东亚和东南亚的许多其他国家的结核病负担、预计糖尿病患病率的大幅上升以及人口规模,它们尤其令人担忧。
在本叙述性综述中,我们旨在:(i)全面了解来自结核病-糖尿病双重负担较高的亚洲国家的结核病-糖尿病流行病学证据;(ii)介绍该地区双向筛查实施的证据;(iii)讨论与亚洲糖尿病患者结核病易感性较高相关的可能因素;(iv)确定结核病-糖尿病合并症治疗面临的挑战。
在PubMed和谷歌学术数据库中检索了所有涉及南亚、东亚和东南亚糖尿病/结核病流行病学、双向筛查和管理的研究。
我们发现结核病患者中的糖尿病患病率约为5%至50%以上,而在亚洲发展中国家,糖尿病患者中的结核病患病率比普通人群高1.8 - 9.5倍。在这些关键地区,针对这两种疾病的诊断和治疗的研究证据以及与糖尿病患者可能的遗传和后天结核病易感性相关的证据都很缺乏。
迫切需要开展更多专门针对该地区适当筛查技术、识别高危患者以及确定两种疾病适当治疗方法的前瞻性研究。